Sign in

NCT07575893Not yet recruitingPhase 1

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

REACH-CD30: Reinduction Therapy Followed by Engineered Autologous CD30.CAR T Cells in Children, Adolescents and Young Adults With Lower-Risk CD30+ Relapsed Classical Hodgkin Lymphoma NYMC 628

Source: ClinicalTrials.gov · Last updated 20 May 2026

Brief summary (registry, in English)

Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
12 (estimated)
First submitted
4 May 2026
Start date
1 Oct 2026
Primary completion date
1 Dec 2031
Lead sponsor
New York Medical College
NCT number
NCT07575893

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 12
  • From 1 Oct 2026 to the primary completion date, 1 Dec 2031
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
  • Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo re-induction therapy.
  • Confirmatory re-biopsy of relapsed CD30+ cHL prior to study entry.
  • Risk Factors: Patient must meet established low-risk factors:
    • Stage at Diagnosis = IA, IIA
    • 12 months from end of therapy OR 3-12 months from end of therapy with ≤3 cycles of treatment and no radiation NO B symptoms NO extra nodal disease at relapse NO relapse in a prior radiation field Stage at Diagnosis = IB, IIB, IIIA
    • 12 months from end of therapy NO B symptoms NO extranodal disease at relapse NO relapse in a prior radiation field
  • Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \< 1% failure rate for protection from pregnancy in the product label.
  • Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.
  • Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • Subject is willing and able to comply with study procedures based on the judgement of the investigator.
  • Planned to undergo reinduction therapy and found to have a favorable response to one line of reinduction therapy. Patients who are refractory to initial reinduction attempts are considered high-risk and thus not eligible for Cell Product Administration and will be removed from study.
    • Exclusion:
  • High-risk relapsed classical Hodgkin Lymphoma with any of the following:
    • B symptoms extra nodal disease at relapse relapse in a prior radiation field
  • Patients under 6 years and over 29 years of age.

Age in the registry: 6 years to 29 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.